New antibody shot could tackle stubborn acne
NCT ID NCT07449156
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a new drug called HB0043, a bispecific antibody that targets two inflammatory proteins (IL-17A and IL-36R) linked to acne. About 21 adults with moderate to severe facial acne will receive either the drug or a placebo. The main goal is to check safety and see if it reduces acne lesions and improves skin appearance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HB0043 (a bispecific antibody targeting IL-17A and IL-36R)
- What this could lead to
- If it works, this could point toward a new treatment option for moderate to severe acne that targets inflammation directly.
- What could go wrong
- This is a very early, small trial (21 people) testing safety first, so it may not show clear benefit. Side effects from blocking immune pathways are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACNE VULGARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dermatology Hospital affiliated to Shandong First Medical University,
Jinan, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentle cream outperform harsh acne drugs?
- Can acne drug harm the eyes? new study investigates
- A new serum aims to clear acne and boost skin confidence
- Head-to-Head: which acne cream works better for clear skin?
- Acne Treatment's Oil-Reducing power put to the test
- AI writes acne guide, students score same as human version